Q3 Earnings Forecast for Journey Medical Issued By B. Riley

Key Points

• B. Riley has revised its Q3 2025 earnings forecast for Journey Medical, now estimating earnings of ($0.01) per share, an improvement from the previous estimate of ($0.02).
• Journey Medical reported a Q2 loss of ($0.16) EPS, missing the consensus estimate of ($0.07) EPS, with a revenue of $15.01 million surpassing estimates.
• The stock price of Journey Medical has declined 4.3% recently, with a current trading price around $6.95 and a 52-week range between $3.54 and $8.90.

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Equities researchers at B. Riley lifted their Q3 2025 earnings per share estimates for shares of Journey Medical in a research report issued on Wednesday, August 13th. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of ($0.01) for the quarter, up from their previous estimate of ($0.02). The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. B. Riley also issued estimates for Journey Medical's Q4 2025 earnings at $0.06 EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at $0.29 EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.09). The firm had revenue of $15.01 million during the quarter, compared to analyst estimates of $14.93 million. Journey Medical had a negative return on equity of 48.69% and a negative net margin of 15.49%.

Several other research analysts have also commented on DERM. Zacks Research lowered Journey Medical from a "hold" rating to a "strong sell" rating in a research report on Friday, August 15th. Lake Street Capital lifted their target price on Journey Medical from $9.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. Alliance Global Partners reiterated a "buy" rating on shares of Journey Medical in a research report on Thursday, May 15th. Finally, Wall Street Zen cut Journey Medical from a "buy" rating to a "hold" rating in a research report on Sunday, July 6th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $11.75.

Journey Medical Stock Performance

Shares of DERM traded up $0.39 during mid-day trading on Monday, hitting $7.47. The stock had a trading volume of 239,603 shares, compared to its average volume of 188,629. The company has a market cap of $174.05 million, a PE ratio of -19.66 and a beta of 0.80. The company's fifty day simple moving average is $7.16 and its two-hundred day simple moving average is $6.59. The company has a quick ratio of 0.95, a current ratio of 1.27 and a debt-to-equity ratio of 1.11. Journey Medical has a fifty-two week low of $3.54 and a fifty-two week high of $8.90.

Hedge Funds Weigh In On Journey Medical

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Tang Capital Management LLC acquired a new position in shares of Journey Medical during the fourth quarter worth approximately $6,747,000. Wasatch Advisors LP boosted its position in shares of Journey Medical by 23.8% during the second quarter. Wasatch Advisors LP now owns 1,152,059 shares of the company's stock worth $8,272,000 after buying an additional 221,456 shares during the period. Cambridge Investment Research Advisors Inc. boosted its position in shares of Journey Medical by 3.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 338,050 shares of the company's stock worth $1,994,000 after buying an additional 9,938 shares during the period. Geode Capital Management LLC boosted its position in shares of Journey Medical by 130.7% during the second quarter. Geode Capital Management LLC now owns 262,353 shares of the company's stock worth $1,884,000 after buying an additional 148,612 shares during the period. Finally, Opaleye Management Inc. boosted its position in shares of Journey Medical by 37.0% during the second quarter. Opaleye Management Inc. now owns 95,000 shares of the company's stock worth $682,000 after buying an additional 25,677 shares during the period. 7.25% of the stock is currently owned by institutional investors and hedge funds.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.